Sharekhan

Metropolis Healthcare Ltd

Thu 13/03/2025,15:54:14 | NSE : Metropolis

₹ 1626.102.85 (0.18%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1615.00

Previous Close

₹ 1623.25

Volume

86124

Mkt Cap ( Rs. Cr)

₹8338.82

High

₹ 1634.20

Low

₹ 1608.10

52 Week High

₹ 2318.30

52 Week Low

₹ 1527.60

Book Value Per Share

₹ 230.87

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Metropolis Healthcare Ltd

Your Vote -

Buy

57.14%

Hold

28.57%

Sell

14.29%

57.14%

21 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1626.10

3

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

3

Option Chain

Analyzes market sentiment, predicts Metropolis Healthcare Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Mar 2025, 6:49PM Schedule of Analyst / Institutional Investor Meeting
  • Metropolis Healthcar - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Mar 2025, 6:49PM Metropolis Healthcare Limited has informed the Exchange about the meeting with investors scheduled on March 11, 2025
  • Metropolis Healthcar - Sale or disposal-XBRL

    4 Mar 2025, 12:32PM Metropolis Healthcare Limited has informed the Exchange regarding Sale or disposal of unit(s)/division(s)/subsidiary
  • Metropolis Healthcar - Acquisition-XBRL

    4 Mar 2025, 12:32PM Metropolis Healthcare Limited has informed the Exchange regarding Acquisition
  • Metropolis Healthcar - Acquisition-XBRL

    4 Mar 2025, 12:31PM Metropolis Healthcare Limited has informed the Exchange regarding Acquisition
  • Metropolis Healthcar - Press Release

    3 Mar 2025, 12:59PM Metropolis Healthcare Limited has informed the Exchange regarding a press release dated March 03, 2025, titled ""Metropolis Healthcare to acquire Agra
  • Metropolis Healthcar - General Updates

    3 Mar 2025, 12:50PM Metropolis Healthcare Limited has informed the Exchange about General Updates
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Acquisition

    3 Mar 2025, 12:50PM Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    3 Mar 2025, 1:00PM Press Release
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    24 Feb 2025, 6:49PM Schedule of Analyst / Institutional Investor Meeting
  • Metropolis Healthcar - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Feb 2025, 6:49PM Metropolis Healthcare Limited has informed the Exchange about the meeting with investors scheduled on March 03, 2025
  • Metropolis Healthcar - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    13 Feb 2025, 5:56PM METROPOLIS HEALTHCARE LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transf
  • Metropolis Healthcar - Resignation

    13 Feb 2025, 5:49PM Metropolis Healthcare Limited has informed the Exchange regarding Resignation of Ms Ishita Medhekar as Chief People Officer of the company w.e.f. Marc
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Change in Management

    13 Feb 2025, 5:49PM Change in Senior Management Personnel
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    11 Feb 2025, 4:23PM Transcript of Q3 FY25 earnings conference call held on Wednesday, February 05, 2025
  • Metropolis Healthcar - Analysts/Institutional Investor Meet/Con. Call Updates

    11 Feb 2025, 4:23PM Metropolis Healthcare Limited has informed the Exchange about Transcript
  • Metropolis Healthcar - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    10 Feb 2025, 11:09PM Scrutinizer's Report
  • Metropolis Healthcar - Shareholders meeting

    10 Feb 2025, 11:06PM Metropolis Healthcare Limited has informed the Exchange regarding Outcome of Postal Ballot. Further, the company has submitted the Exchange a copy of
  • Metropolis Healthcar - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    10 Feb 2025, 11:05PM Outcome of Postal Ballot
  • Metropolis Healthcar - Update-Acquisition/Scheme/Sale/Disposal-XBRL

    7 Feb 2025, 4:55PM Metropolis Healthcare Limited has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
  • Metropolis Healthcar - General Updates

    6 Feb 2025, 5:15PM Metropolis Healthcare Limited has informed the Exchange about Update on acquisition of Core Diagnostics Private Limited
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Updates on Acquisition

    6 Feb 2025, 5:15PM Update on acquisition of Core Diagnostics Private Limited
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    5 Feb 2025, 4:54PM Schedule of Analyst/Institutional Investor Meeting
  • Metropolis Healthcar - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Feb 2025, 4:54PM Metropolis Healthcare Limited has informed the Exchange about Schedule of meet
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    5 Feb 2025, 4:44PM Link of audio recording of the earnings conference call held on February 05, 2025
  • Metropolis Healthcar - Analysts/Institutional Investor Meet/Con. Call Updates

    5 Feb 2025, 4:44PM Metropolis Healthcare Limited has informed the Exchange about Link of Recording
  • Metropolis Healthcar - Copy of Newspaper Publication

    5 Feb 2025, 4:34PM Metropolis Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
  • Metropolis Healthcar - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    4 Feb 2025, 7:40PM METROPOLIS HEALTHCARE LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transf
  • Metropolis Healthcar - Investor Presentation

    4 Feb 2025, 7:12PM Metropolis Healthcare Limited has informed the Exchange about Investor Presentation
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Investor Presentation

    4 Feb 2025, 7:12PM Investor Presentation for the quarter ended December 31, 2024
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    4 Feb 2025, 6:57PM Press Release
  • Metropolis Healthcar - Press Release

    4 Feb 2025, 6:56PM Metropolis Healthcare Limited has informed the Exchange regarding a press release dated February 04, 2025, titled ""Metropolis Healthcare s PAT up by
  • Metropolis Healthcar - Integrated Filing- Financial

    4 Feb 2025, 6:44PM Integrated Filing (Financial) for the quarter ended December 31, 2024
  • Metropolis Healthcar - Integrated Filing (Financial)

    4 Feb 2025, 6:35PM Integrated Filing (Financial) for the quarter ended December 31, 2024
  • Metropolis Healthcar Q3 net profit up 2.62% at Rs 27.40 cr

    4 Feb 2025, 6:31PM The company reported standalone net profit of Rs 27.40 crore for the quarter ended December 31, 2024 as compared to Rs 26.70 crore in the same period
  • Metropolis Healthcar - Outcome of Board Meeting

    4 Feb 2025, 6:00PM Metropolis Healthcare Limited has informed the Exchange regarding Board meeting held on February 04, 2025.
  • Metropolis Healthcar - Board Meeting Outcome for The Meeting Held Today (February 04, 2025)

    4 Feb 2025, 6:00PM Outcome of Board Meeting held on Tuesday, February 04, 2025
  • Metropolis Healthcar - Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months

    4 Feb 2025, 5:55PM Unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31, 2024
  • Metropolis Healthcar - Financial Result Updates

    4 Feb 2025, 5:55PM Metropolis Healthcare Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Feb 2025, 2:50PM Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the officia
  • Metropolis Healthcar - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Feb 2025, 2:50PM Metropolis Healthcare Limited has informed the Exchange about the meeting with investors scheduled on February 11, 2025
  • Metropolis Healthcar - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    29 Jan 2025, 6:40PM METROPOLIS HEALTHCARE LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transf
  • Metropolis Healthcar - Resignation

    29 Jan 2025, 6:25PM Metropolis Healthcare Limited has informed the Exchange regarding Resignation of Mr Balakrishnan Janardhanan as Chief Business Officer (South-East) of
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Change in Management

    29 Jan 2025, 6:24PM Change in Senior Management Personnel
  • Metropolis Healthcar - Board Meeting Intimation

    29 Jan 2025, 4:03PM Metropolis Healthcare Limited has informed the Exchange about Board Meeting to be held on 04-Feb-2025 to inter-alia consider and approve the Unaudited
  • Metropolis Healthcar - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    29 Jan 2025, 3:55PM The Company will participate in the Q3 FY25 earnings conference call (i.e. post earnings/quarterly call), organized by IIFL Capital on Wednesday, Febr
  • Metropolis Healthcar - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Jan 2025, 3:55PM Metropolis Healthcare Limited has informed the Exchange about Schedule of meet Q3 FY25 earnings conference call (i.e. post earnings/quarterly call), o
  • Metropolis Healthcar - Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Finan

    29 Jan 2025, 3:44PM Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 ,inter alia, to conside
  • Metropolis Healthcar has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    20 Jan 2025, 8:30PM As of December 2024, 49.40% is owned by Indian Promoters and 50.60% by Public. <p align=justify> Institutional holds 46.73% (Insurance Companies 3.50%
  • Metropolis Healthcar - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Jan 2025, 8:18PM Metropolis Healthcare Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations,
  • Metropolis Healthcar - Updates

    6 Jan 2025, 8:12PM Metropolis Healthcare Limited has informed the Exchange regarding ''Change in the name of the Registrar and Transfer Agent of the Company""
  • Metropolis Healthcar - Change In The Name Of The Registrar And Transfer Agent Of The Company

    6 Jan 2025, 7:48PM Change in the name of the Registrar and Transfer Agent of the Company
  • Metropolis Healthcar - Updates

    6 Jan 2025, 1:10PM Metropolis Healthcare Limited has informed the Exchange regarding 'Business update for Q3FY25'.
  • Metropolis Healthcar - Business Update For Q3FY25

    6 Jan 2025, 1:09PM Business update for Q3FY25
  • Metropolis Healthcar - Trading Window-XBRL

    31 Dec 2024, 3:57PM Metropolis Healthcare Limited has informed the Exchange about Closure of Trading Window
  • Metropolis Healthcar - Trading Window

    31 Dec 2024, 3:44PM Metropolis Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulat
  • Metropolis Healthcar - Incorporation-XBRL

    25 Dec 2024, 10:56PM Metropolis Healthcare Limited has informed the Exchange regarding Incorporation
  • Metropolis Healthcar - General Updates

    25 Dec 2024, 10:52PM Metropolis Healthcare Limited has informed the Exchange that pursuant to Regulation 30 read with Para A of Part A of Schedule III of Listing Regulatio
  • Metropolis Healthcar - Analysts/Institutional Investor Meet/Con. Call Updates

    16 Dec 2024, 1:16PM Metropolis Healthcare Limited has informed the Exchange about Transcript
  • Metropolis Healthcar - Transcript Of Investor Conference Call

    16 Dec 2024, 5:00PM Transcript of investor conference call held on December 10, 2024
  • Metropolis Healthcare

    10 Dec 2024 , 10:39AM The company acquired Core Diagnostics for Rs 247 crore to become a leading cancer testing company. This strategic acquisition will enhance Metropolis' capabilities in advanced cancer testing, while deepening its presence in northern and eastern India and driving market-share expansion in the specialised segment across the country. Positive
  • Metropolis Healhcare

    17 Jul 2023 , 10:19AM Announced business update for Q1FY24 by which core business' revenue growth was at ~ 12% y-o-y while total revenue from operations for Q1FY24 was marginally negative y-o-y due to covid and B2G contract. Revenue per test for core business was up by 3% y-o-y and revenue per patient was flat due to expiration of B2G contract. B2C revenue was up 12% y-o-y. Premium wellness segment increased 23% y-o-y while gross debt stood at ₹67 Cr. We do not have it in coverage. Q1FY24 witnessed seasonal impact on margins which was further impacted by the in source B2G business which resulted in lower margins. The company expects the margin trajectory to improve in the rest of the FY. Positive for the stock.
  • Metropolis Healthcare

    4 Jul 2022 , 11:17AM The Mumbai bench of the NCLT has approved the scheme of amalgamation and arrangement of Merger by Absorption of its wholly owned subsidiaries - Bokil Golwilkar Metropolis Healthcare Private Limited, Desai Metropolis Health Services Private Limited, Dr. Patel Metropolis Healthcare Private Limited, Lab One Metropolis Healthcare Services Private Limited, Micron Metropolis Healthcare Private Limited, R. V. Metropolis Diagnostic & Health Care Center Private Limited, Raj Metropolis Healthcare Private Limited and Sudharma Metropolis Health Services Private Limited with the company. The amalgamation and arrangement of merger is unlikely to have any material impact on the financials of Metropolis going ahead as the companies merged were wholly owned subsidiaries of Metropolis.
  • Metropolis Healthcare

    14 Jun 2022 , 11:02AM Following various news reports which mentions of the company continuously exploring various strategic options/investment opportunities. To these the promoters and the management team has clarified that they are committed to operating the business and have no plans of exiting the business, however they keep on getting inbound interest from Financial Institutions and Companies for a potential minority stake purchase in MHL. The promoter’s clarification to this is sentimentally positive.
  • Metropolis Healthcare

    23 May 2022 , 10:47AM As per media news the management is looking to raise funds and is in talks to sell a minority stake in the company to leading e-tailers like Flipkart, Amazon. Also it is in talks with Apollo Hospitals for the same. With the e-tailers gaining grounds in the recent past, it could have a positive rub off effect on Metropolis if the company management is able to sell some stake to an etailer and which in turn could enable grow its B2C segment.
  • Viewpoint – Metropolis Healthcare

    16 Mar 2022 , 12:06PM Viewpoint – Metropolis Healthcare: Near-term concerns apparent; Long-term levers intact
  • Metropolis Healthcare

    23 Dec 2021 , 12:05PM Over the next three years plans for setting up 90 new labs and 1800 new collection centres with most of the expansion being done in its focus cities. As on September 2021 the company operates 132 labs and 3006 collection centres across India. Secondly on the international markets, the company has a presence in the few Africa markets like Kenya, Zambia and Ghana and now it plans to further penetrate these markets and looks to establish its leadership position in these markets. Also it could look to enter 1-2 new markets in the region and plans to leverage the retail as well as the B2B model in these markets for growth. Positive read thru
  • Metropolis Healthcare

    26 Nov 2021 , 11:23AM Plans to invest Rs 50 cr over the next three years for setting up 90 new labs and 1800 new collection centres with most of the expansion being done in its focus cities. As on September 2021 the company operates 132 labs and 3006 collection centres. It has added 7 new labs and 451 collection centres and plans to end FY2022 by adding at least 25 laboratories and 700-750 collection centres. Also it plans to invest Rs 15-20 crore per year on digitalization and also aims to increase the share of specialized tests to 50% from 43% now. Network expansion and expected increase in share of specialized tests are key positive and could aid earnings growth. We have a Positive view on the company
  • Viewpoint: Metropolis Healthcare

    12 Nov 2021 , 11:59AM Viewpoint: Metropolis Healthcare Q2FY22 Results Update
  • Metropolis Healthcare Q2FY22

    11 Nov 2021 , 10:33AM Metropolis Healthcare Q2FY22: muted Quarter; Results marginally miss estimates
  • CRISIL raises Metropolis’ ratings

    21 Oct 2021 , 12:46PM The revision in outlook is on the back of expected strengthening of the business over the medium term
  • Metropolis Healthcare

    18 Oct 2021 , 10:02AM The board of directors of the company have approved the deal to acquire Hitech Diagnostics Center along with its subsidiary Centralab. Earlier the company had terminated the deal which has now been re-approved. The consideration for the deal has been revised to Rs 636 cr in cash only as against the earlier consideration of RS 511 cr cash and equity consideration of upto 495000 fully paid-up equity shares of Rs. 2 each. The indicative timeline for completion of the proposed acquisition is 6 months. Positive as the acquisition would bring in synergies in the form of geographic expansion for Metropolis.
  • Viewpoint: Metropolis Healthcare

    4 Oct 2021 , 10:50AM Viewpoint: Metropolis Healthcare – Charting a Strong growth trajectory
  • Metropolis launch new laboratory in Kochi

    5 Feb 2021 , 11:58AM New laboratory spread across four floors and 5000 sqft with latest technology and equipment
  • Metroplis Healthcare

    3 Aug 2020 , 11:53AM The promoters are planning to offload stakes worth $40mn (Rs 300 cr) at a floor price of Rs 1300 per share as compared to the previous close price of Rs 1569. The selling price is at a discount to the previous close price and the deals have an upsize option. Currently, the promoters stake in the company stands at 50.81%.
  • Metropolis Healthcare

    24 Jun 2020 , 9:48AM The promoters – Dr Sushil Kanubhai Shah and Dr Duru Sushil Shah to offload a part of their stakes through a block deal which would happen on 24th June 2020 (Today). Both the promoters together look to sell stake of 4.59% of the total shares outstanding through accelerated book building offer. Dr Sushil Shah holds 7.36% stake in the company while Dr Duru Shah holds 18.19% stake. The floor price for the deal is Rs 1300, which is at a 10.4% discount to the closing price of Rs 1452.4 as on 23rd June 2020. Cumulatively the size of the deal is pegged at Rs 304.2 cr. Post the deal the promoters stake will come down to 52.31% from 56.9% now.
  • Metropolis Healthcare

    15 Apr 2020 , 10:05AM CA Lotus Investments – “Carlyle” looks to sell its stake in Metropolis Heathcare Ltd through accelerated book build offer in the secondary markets (Block deal) on 15th April 2020 (today). Carlye would be selling 6.55 mn shares, ~13% of the total shares outstanding (Caryle holds 14.3% stake) at a floor price of Rs 1,110 per share, which is a 17% discount to the closing price as on 13th April 2020.

Key fundamentals

Evaluate the intrinsic value of Metropolis Healthcare Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 1031.1872 1018.3087 1082.6745 708.9253 512.3846
Liabilities 1031.1872 1018.3087 1082.6745 708.9253 512.3846
Equity 10.2454 10.2421 10.2343 10.2233 10.1261
Gross Profit 258.4812 269.3104 305.0844 239.3733 172.6047
Net Profit 115.8898 138.9473 192.2414 197.5551 112.0543
Cash From Operating Activities 269.0076 237.7385 237.1506 202.4967 156.1298
NPM(%) 10.5 13.03 17.2 24.2 16.84
Revenue 1103.4254 1066.0407 1117.1306 816.1083 665.3071
Expenses 844.9442 796.7303 812.0462 576.735 492.7024
ROE(%) 9.78 11.73 16.23 16.68 9.46

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
17 Nov 2023 4 200 0 1571.55
23 Feb 2023 8 400 0 1249.75
21 Feb 2022 8 400 0 2560.4
17 Feb 2021 8 400 0 2228.5
13 Feb 2020 8 400 0 1586.25

Peers

Other companies within the same industry or sector that are comparable to Metropolis Healthcare Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 925.85 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 3373.68 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 1738.92 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 3181.09 -239.30 0.00

Company Info

Dr. Sushil Kanubhai Shah, one of The Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards. In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners, in the name and style of Metropolis Lab. In January 1998, Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1, 2002, the business of Metropolis Lab was transferred to Dr. V. K. Desai's Hospital as a going concern. In May 2002, Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai's Hospital was changed to Metropolis Health Services in November 2002. Further, in April 2003, Ameera Sushil Shah, Jaswanti Kanubhai Shah, Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services.In July 2003, Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited ("MHSIPL") under the Companies Act, 1956. The name of MHSIPL was changed to Metropolis Health Services (India) Limited ("MHSIL") pursuant to a `Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' granted by RoC on March 1, 2006. In January 2009, MHSIL amalgamated with Pathnet India Private Limited, which was a wholly owned subsidiary of MHSIL. For details, see "- Scheme of amalgamation between Pathnet India Private Limited and Metropolis Health Services (India) Limited, Metro Home Health Services Private Limited, Lister Metropolis Laboratory and Research Centre Private Limited, Tripoli Path Lab Private Limited and Diwanchand Metropolis Diagnostics Services Private Limited".Pathnet India Private Limited was incorporated at New Delhi as a private limited company under the Companies Act, 1956 pursuant to the `Certificate of Incorporation' granted by the Registrar of Companies, N. C. T. of Delhi and Haryana on November 10, 2000. The name of The Company was changed to Pathnet India Limited pursuant to a `Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' granted by RoC on July 1, 2009. The name of The Company was changed to Metropolis Healthcare Limited pursuant to a `Fresh Certificate of Incorporation Consequent upon Change of Name' granted by RoC on September 23, 2009. Major events and milestones of The Company :2002-First major acquisition by the Company of Sudharma2004-The Company was accredited by National Accreditation Board for Testing and Calibration Laboratories (Department of Science & Technology, India)2005-The Company received accreditation from The College of American Pathologists2006-Investment by The Western India Trustee and Executor Company in the Company-Acquisition of M/s. Lister Laboratory and Research Centre Private Limited in Chennai2007-Acquisition of Desai Clinical Laboratory in Surat2008-Acquisition of R.V Diagnostics & Healthcare Center Private Limited in Bangalore2009-Scheme of Amalgamation 20092010-Investment by Foxcreek Investment Limited in the Company2011-Acquisition of LabOne in Raipur2012-Acquisition of Micron Laboratories in Mumbai-Acquisition of subsidiary in Kenya-Acquisition of Dr. Patel Pathology Laboratory Private Limited in Nashik-Incorporation of subsidiary in Mauritius2013-Acquisition of M/s. Ekopath Center-Pathology and Cytology Division in Guwahati-Establishment of GRL in Mumbai2014-Acquisition of subsidiary in Ghana2015-Investment by CA Lotus Investments in the Company-Incorporation of subsidiary in Uganda-Incorporation of branch office in Zambia2017-Acquisition of Sanjeevani Pathology Laboratory in Rajkot2018-Public-Private partnership agreement executed with National AIDS Control Organisation, Government of India-Scheme of Amalgamation 2018-Incorporation of subsidiary in Tanzania  Awards, achievements and certifications :2010-The Company was awarded the "Diagnostic Services Company of the Year" by Frost & Sullivan2012-The Company was felicitated for providing "Outstanding Quality Diagnostic Services" by HIV Congress 20122014-The Company was awarded the "Most Promising Brand" by the World Consulting and Research Corporation-The Company was awarded as a "Quality Brand" by Quality Brands India2015-The Company was awarded the "Best Diagnostic Company of the Year" at the National Awards for Excellence in Healthcare 2015-The Company was awarded the "Diagnostic Services Company of the Year" by the VCCircle Network-The Company was awarded for "Excellence in Productive Employment Creation" by Business Today2018-The Company was awarded for "Best in Health and Fitness" in the Digital Campaign Awards by LH Insights-The Company was awarded for "Excellence in Customer Service & Delivery" by Biotrains-The Company was awarded special jury mention for "Service Excellence (Diagnostic Centre)" by FICCI at the Healthcare Excellence Awards2018-2019-The Company was awarded "Iconic Pathology Lab Mumbai" by Midday Health & Wellness Icons 2020 -Metropolis Healthcare wins India CSR award for "Too Shy To Ask" App. -India Diagnostic service provider company of the year 2020.

Dr. Sushil Kanubhai Shah, one of The Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards. In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners, in the name and style of Metropolis Lab. In January 1998, Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1, 2002, the business of Metropolis Lab was transferred to Dr. V. K. Desai's Hospital as a going concern. In May 2002, Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai's Hospital was changed to Metropolis Health Services in November 2002. Further, in April 2003, Ameera Sushil Shah, Jaswanti Kanubhai Shah, Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services.In July 2003, Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited ("MHSIPL") under the Companies Act, 1956. The name of MHSIPL was changed to Metropolis Health Services (India) Limited ("MHSIL") pursuant to a `Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' granted by RoC on March 1, 2006. In January 2009, MHSIL amalgamated with Pathnet India Private Limited, which was a wholly owned subsidiary of MHSIL. For details, see "- Scheme of amalgamation between Pathnet India Private Limited and Metropolis Health Services (India) Limited, Metro Home Health Services Private Limited, Lister Metropolis Laboratory and Research Centre Private Limited, Tripoli Path Lab Private Limited and Diwanchand Metropolis Diagnostics Services Private Limited".Pathnet India Private Limited was incorporated at New Delhi as a private limited company under the Companies Act, 1956 pursuant to the `Certificate of Incorporation' granted by the Registrar of Companies, N. C. T. of Delhi and Haryana on November 10, 2000. The name of The Company was changed to Pathnet India Limited pursuant to a `Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' granted by RoC on July 1, 2009. The name of The Company was changed to Metropolis Healthcare Limited pursuant to a `Fresh Certificate of Incorporation Consequent upon Change of Name' granted by RoC on September 23, 2009. Major events and milestones of The Company :2002-First major acquisition by the Company of Sudharma2004-The Company was accredited by National Accreditation Board for Testing and Calibration Laboratories (Department of Science & Technology, India)2005-The Company received accreditation from The College of American Pathologists2006-Investment by The Western India Trustee and Executor Company in the Company-Acquisition of M/s. Lister Laboratory and Research Centre Private Limited in Chennai2007-Acquisition of Desai Clinical Laboratory in Surat2008-Acquisition of R.V Diagnostics & Healthcare Center Private Limited in Bangalore2009-Scheme of Amalgamation 20092010-Investment by Foxcreek Investment Limited in the Company2011-Acquisition of LabOne in Raipur2012-Acquisition of Micron Laboratories in Mumbai-Acquisition of subsidiary in Kenya-Acquisition of Dr. Patel Pathology Laboratory Private Limited in Nashik-Incorporation of subsidiary in Mauritius2013-Acquisition of M/s. Ekopath Center-Pathology and Cytology Division in Guwahati-Establishment of GRL in Mumbai2014-Acquisition of subsidiary in Ghana2015-Investment by CA Lotus Investments in the Company-Incorporation of subsidiary in Uganda-Incorporation of branch office in Zambia2017-Acquisition of Sanjeevani Pathology Laboratory in Rajkot2018-Public-Private partnership agreement executed with National AIDS Control Organisation, Government of India-Scheme of Amalgamation 2018-Incorporation of subsidiary in Tanzania  Awards, achievements and certifications :2010-The Company was awarded the "Diagnostic Services Company of the Year" by Frost & Sullivan2012-The Company was felicitated for providing "Outstanding Quality Diagnostic Services" by HIV Congress 20122014-The Company was awarded the "Most Promising Brand" by the World Consulting and Research Corporation-The Company was awarded as a "Quality Brand" by Quality Brands India2015-The Company was awarded the "Best Diagnostic Company of the Year" at the National Awards for Excellence in Healthcare 2015-The Company was awarded the "Diagnostic Services Company of the Year" by the VCCircle Network-The Company was awarded for "Excellence in Productive Employment Creation" by Business Today2018-The Company was awarded for "Best in Health and Fitness" in the Digital Campaign Awards by LH Insights-The Company was awarded for "Excellence in Customer Service & Delivery" by Biotrains-The Company was awarded special jury mention for "Service Excellence (Diagnostic Centre)" by FICCI at the Healthcare Excellence Awards2018-2019-The Company was awarded "Iconic Pathology Lab Mumbai" by Midday Health & Wellness Icons 2020 -Metropolis Healthcare wins India CSR award for "Too Shy To Ask" App. -India Diagnostic service provider company of the year 2020.

Read More

Parent Organisation

Metropolis Healthcare Ltd.

Founded

01/03/2006

Managing Director

Mrs.Ameera Sushil Shah

NSE Symbol

METROPOLISEQ

FAQ

The current price of Metropolis Healthcare Ltd is ₹ 1626.10.

The 52-week high for Metropolis Healthcare Ltd is ₹ 1634.20 and the 52-week low is ₹ 1608.10.

The market capitalization of Metropolis Healthcare Ltd is currently ₹ 8338.82. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Metropolis Healthcare Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Metropolis Healthcare Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Metropolis Healthcare Ltd shares.

The CEO of Metropolis Healthcare Ltd is Mrs.Ameera Sushil Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT